QGold Resources Engages SLR to Advance Permitting for Quartz Mountain Gold Project

Ovid Therapeutics has appointed Petra Kaufmann as Chief Medical Officer. Kaufmann brings extensive experience in CNS therapeutic development, having led clinical trials from first-in-human to global regulatory approval. She joins Ovid with a focus on advancing the Company's clinical pipeline of potential best- and first-in-class therapeutic candidates for conditions and symptoms driven by neuronal imbalance. Kaufmann will guide clinical, medical, and regulatory strategy for OV329 and Ovid's broad portfolio of first-in-class KCC2 direct activators.